The Elixir Factor, Lilly’s new podcast hosted by Joe Kim, senior advisor of patient experience and design, explores the factors that inspire bold advances in science, innovation and the resilience required to change history. Tune in to hear how the Lilly research and development team collaborates with partners in advocacy, technology, academia and policy to seek cures or solutions for the most difficult diseases. There is always a way to get better at what you are doing – simply say “yes” to the next step. Say yes and subscribe today!
S2 Ep7: Protecting Ideas Drives Innovation
Good science drives innovation. One of the most critical ingredients for an innovation-friendly environment is a strong intellectual property (IP) framework. It allows for collaboration, partnership and larger investments that provide an opportunity to scale research, which in turn can provide a great opportunity for success, and hopefully advance the development of medicines for patients. The U.S. is the global leader of biopharmaceutical innovation because its IP system promotes competition, ensuring each player excels at their role and is incentivized to take risks and share information throughout the process. Joe talks to Dr. John Stewart IV, professor of surgery and physician executive for oncology sciences at University of Illinois College of Medicine at Chicago, about the factors that have influenced his oncology research and how he has been able to continue this research through partnerships and policies that support IP. Joe also talks to Tonya Combs, vice president and deputy general patent counsel of IP procurement at Lilly, about the drug discovery process, the Bayh-Dole Act and the biopharmaceutical research ecosystem during the COVID-19 pandemic.
S2 Ep6: Dominantly Inherited Alzheimer’s Disease: A View From Within
Dominantly Inherited Alzheimer’s Disease (DIAD) is a rare form of Alzheimer’s disease that causes memory loss and dementia in people typically in their 30s to 50s. The disease affects less than 1 percent of the total population and is devastating to those who are impacted by it, including their families. Joe talks to Dr. Randy Bateman, the Charles F. and Joanne Knight Distinguished Professor of Neurology, director and principal investigator of DIAN-TU and Dr. Roy Yaari, senior medical advisor of neurodegeneration at Lilly, about DIAD, the factors that were considered in the design of the DIAN-TU Study, and AD research in clinical trials. Joe also talks to patient advocate Daisy Duarte about her family experience with DIAD and why she advocates for LatinosAgainst Alzheimer’s.
S2 Ep5: Adopting A Scientist’s Mentality During Uncertain Times
Health literacy is about a person’s ability to not just read, but to understand and act on health information to help optimize health outcomes. Patients are more responsible for their own health education than ever before. Clear health communication is one of the easiest ways to help those with limited health literacy. During this global COVID-19 pandemic, there has been an overflow of conflicting health information. Joe talks to Dr. Linda Neuhauser, Clinical Professor of Community Health and Human Development at UC Berkeley, School of Public Health, and Co-Principal Investigator of Health Research for Action, and Lori Hall, Advisor of Global Health Literacy at Lilly, about the factors that contribute to the complexity of health information, health care, concepts that have been used by scientists and the media in describing our understanding of the pandemic, and their hope in science to lead us to answers.
S2 Ep4: A Biotech Mindset & The Drive to Discover Targeted Cancer Treatments
The promise of science to change people’s lives has never been greater. Recent progress in understanding biology, including the sequencing of the human genome, has led to new insights — allowing scientists more power and precision to treat disease, including cancer. As the understanding of cancer grows, scientists have found that it’s actually not a single disease but a collection of diseases that are driven by various causes or genetic breakdowns. Joe talks to Pete Nicholas, co-founder of Boston Scientific about his diagnosis of a very aggressive form of non-small cell lung cancer. Joe also talks to Anne White, President of Lilly Oncology, about the factors that came into play to redesign a traditional oncology research and development organization into a biotech and how this new mindset has the potential to develop more medicines for people living with cancer.
S2 Ep3: Brain Health & The Be Brain Powerful™ Campaign
Brain health is one of the most urgent issues for our healthcare system, our economy, and our country. Evidence is strong that people can reduce their risk of cognitive decline by making conscious lifestyle changes like regular physical activity and participating in social engagements. Joe talks to Brooks Kenny, Executive Director of WomenAgainstAlzheimer’s, about the factors that inspired the launch of The Be Brain Powerful® Campaign and its goals to change the path for both women and brain health. Joe also talks to Vera Maljkovic, Principal Researcher & Clinical Psychologist in Cognition and Behavior, and Jen Zimmer, Sr. Medical Advisor in Alzheimer’s Research, from Lilly about how we measure the health of our brains, the effects of Alzheimer’s disease on the brain, and what it can mean for cognitive decline.
S2 Ep2: Skin Related Diseases Are More Than Skin Deep
What is the body’s largest organ, coming in a variety of colors and weighing in at about 6 pounds? The skin. It’s one of the most familiar aspects of our bodies and our health. Skin related diseases are more than skin deep and can have devastating effects on people’s lives. There are an estimated 10 million patients in the U.S. with moderate-to-severe-atopic dermatitis.
Joe talks with two of our own Lilly scientists, Dr. Lotus Mallbris and Alison Budelsky, about the unmet needs for patients with immunological conditions. Hear what factors influence dermatology and immunology research and why diversity of thought is critical in this space. Joe also talks to Julie Maxwell about the impact atopic dermatitis has had on her life.